Immatics N.V.
Immatics N.V. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma on January 15, 2028. There are 3 upcoming events on record.
Cash runway is approximately 38.4 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| January 15, 2028 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Trial Milestone | Phase 3 |
| December 15, 2028 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
| August 15, 2029 | ACTengine® IMA203 Combined With mRNA-4203 | Trial Milestone | Phase 1 |
Track IMTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open IMTX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.